It is proposed that this article be deleted because of the following concern:
If you can address this concern by improving, copyediting, sourcing, renaming, redirecting, or merging the page, please edit this page and do so. You may remove this message if you improve the article or otherwise object to deletion for any reason. Although not required, you are encouraged to explain why you object to the deletion, either in your edit summary or on the talk page. If this template is removed, do not replace it. The article may be deleted if this message remains in place for seven days, i.e., after 18:33, 23 November 2026 (UTC). Find sources: "Recombinant Immunotoxin Collaborative Group" – news · newspapers · books · scholar · JSTOR |
The Recombinant Immunotoxin Collaborative Group (RICG) is a group of scientists specialising in immunology, biochemistry and molecular biology from the United Kingdom and Italy. The group is working toward the development of genetically engineered immunotoxins made from monoclonal antibody fragments genetically fused to either saporin or Pseudomonas exotoxin (PE) for the treatment of human hematological malignancies such as leukaemia, lymphoma and multiple myeloma.
The RICG was formed in 2005 and originally consisted of Dr Aldo Ceriotti and Dr M. Serena Fabbrini (IBBA, CNR, Milan), Professor Marco Colombatti (University of Verona), Professor Rodolfo Ippoliti (University of L'Aquila), Dr Alessandro Pini (University of Siena) and Drs David Flavell and Sopsamorn Flavell (University of Southampton Medical School and Leukaemia Busters). Dr Alessandro Pini left the group in 2007.[citation needed]
The RICG was successful in producing a range of recombinant immunotoxins based on the monoclonal antibodies 4KB128 and OKT10 targeting CD22 and CD38, respectively on normal and malignant lymphoid cells. This development work was undertaken with funding from the UK-based charity Leukaemia Busters under the direction of Dr David Flavell, the charity's Scientific Director
The group disbanded in 2009 due to funding difficulties following the global economic crisis but despite this the former members continue to collaborate in areas of mutual interest. In this respect some of the group members and their respective institutes have recently entered into a collaboration agreement with the Italian pharmaceutical company Dompé based in L’Aquila, central Italy with the intention of developing one of the RICG produced recombinant immunotoxins for investigation in early phase clinical trials for patients with leukaemia and lymphoma.[citation needed]